Year archive

HBM Holdings Limited — 2021 filings

All 51 regulatory filings released by HBM Holdings Limited (2142) in 2021, sourced directly from the official regulator.

51 Filings

2021 Period

2021 filings (51)

Filing	Released	Lang
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE BY THE TRUSTEE PURSUANT TO THE SHARE AWARD SCHEME Transaction in Own Shares	2021-12-29	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2021 Regulatory Filings	2021-12-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2021 Regulatory Filings	2021-11-05	English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST DOSING OF FIRST PATIENT WITH BATOCLIMAB (HBM9161) PHASE II TRIAL FOR TREATMENT OF THYROID EYE DISEASE Regulatory Filings	2021-10-19	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2021 Regulatory Filings	2021-10-07	English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST DOSING OF FIRST PATIENT WITH BATOCLIMAB (HBM9161) PHASE III TRIAL FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS Regulatory Filings	2021-09-27	English
Interim Report 2021 Interim / Quarterly Report	2021-09-20	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Board/Management Information	2021-09-17	English
CHANGE OF EXECUTIVE DIRECTOR Board/Management Information	2021-09-17	English
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS FROM PHASE I STUDY AND ABSTRACTS OF PHASE I DATA OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY HBM4003 Regulatory Filings	2021-09-13	English
VOLUNTARY ANNOUNCEMENT - CHINESE REGULATORY APPROVAL OF TWO IND APPLICATIONS FOR NEXT-GENERATION ANTI-CTLA-4 ANTIBODY HBM4003 Regulatory Filings	2021-09-10	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2021 Regulatory Filings	2021-09-06	English
VOLUNTARY ANNOUNCEMENT - HARBOUR BIOMED RECEIVES CHINESE REGULATORY APPROVAL OF IND APPLICATION TO BEGIN PHASE II CLINICAL TRIAL OF HBM9161 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) Regulatory Filings	2021-08-31	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021 Interim / Quarterly Report	2021-08-30	English
DATE OF BOARD MEETING Report Publication Announcement	2021-08-18	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2021 Share Issue/Capital Change	2021-08-05	English
2020 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Environmental & Social Information	2021-07-26	English
VOLUNTARY ANNOUNCEMENT - ABSTRACTS OF PHASE I DATA OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY HBM4003 TO BE PRESENTED AT ESMO CONGRESS 2021 Regulatory Filings	2021-07-26	English
APPOINTMENT OF CHIEF FINANCIAL OFFICER Board/Management Information	2021-07-20	English
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON A COLLABORATION AGREEMENT WITH THE MOUNT SINAI HEALTH SYSTEM AND IN CONNECTION WITH NEUTRALIZING COVID-19 ANTIBODY Regulatory Filings	2021-07-19	English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST DOSING OF LAST PATIENT WITH BATOCLIMAB (HBM9161) PHASE Ib/IIa TRIAL FOR TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDER Regulatory Filings	2021-07-16	English
APPOINTMENT OF JOINT COMPANY SECRETARY AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES Board/Management Information	2021-07-13	English
VOLUNTARY ANNOUNCEMENT - POSITIVE TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF BATOCLIMAB (HBM9161) IN GENERALIZED MYASTHENIA GRAVIS Capital/Financing Update	2021-07-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2021 Regulatory Filings	2021-07-05	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 21 JUNE 2021 Declaration of Voting Results & Voting Rights Announcements	2021-06-21	English
VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT OF NEXT-GEN ANTI-CTLA-4 ANTIBODY HBM4003 IN COMBINATION WITH PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) ANTIBODY IN PATIENTS WITH ADVANCED NON-SMALL CELL Regulatory Filings	2021-06-17	English
VOLUNTARY ANNOUNCEMENT - HARBOUR BIOMED AND DANA-FARBER CANCER INSTITUTE COLLABORATE TO ADVANCE NOVEL BIOTHERAPIES FOR CANCER TREATMENT Regulatory Filings	2021-06-16	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Governance Information	2021-06-09	English
REDESIGNATION OF DIRECTOR; APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND CHANGE IN THE COMPOSITION OF BOARD COMMITTEES Board/Management Information	2021-06-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2021 Capital/Financing Update	2021-06-04	English
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON THE ONGOING CLINICAL STUDIES FOR BATOCLIMAB (HBM9161) Regulatory Filings	2021-06-02	English
VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT IN PHASE Ib/IIa CLINICAL STUDY OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY IN AUSTRALIA Regulatory Filings	2021-05-11	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2021 Share Issue/Capital Change	2021-05-06	English
PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING AGM Information	2021-04-28	English
NOTICE OF ANNUAL GENERAL MEETING AGM Information	2021-04-28	English
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING AGM Information	2021-04-28	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Board/Management Information	2021-04-26	English
RESIGNATION OF DIRECTOR Board/Management Information	2021-04-26	English
Annual Report 2020 Annual Report	2021-04-20	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021 Share Issue/Capital Change	2021-04-09	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2020 Annual Report	2021-03-29	English
VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT IN PHASE I CLINICAL STUDY OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY IN CHINA Regulatory Filings	2021-03-22	English
VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT IN TANFANERCEPT (HBM9036) PHASE III CLINICAL TRIAL Regulatory Filings	2021-03-11	English
DATE OF BOARD MEETING Report Publication Announcement	2021-03-10	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021 Regulatory Filings	2021-03-03	English
VOLUNTARY ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED APPROVAL OF THE INVESTIGATIONAL NEW DRUG APPLICATION FOR COMBINATION THERAPY OF HBM4003, A NEXT-GENERATION, FULLY HUMAN ANTI-C Regulatory Filings	2021-02-26	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2021 Regulatory Filings	2021-02-03	English
INSIDE INFORMATION - UPDATE ON BATOCLIMAB (HBM9161) Regulatory Filings	2021-02-02	English
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE GRANT OF BREAKTHROUGH THERAPY DESIGNATION TO BATOCLIMAB (HBM9161) BY CHINA CENTER FOR DRUG EVALUATION Regulatory Filings	2021-01-28	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020 Share Issue/Capital Change	2021-01-07	English
STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF OVER-ALLOTMENT OPTION Capital/Financing Update	2021-01-03	English